Glenmark Pharmaceuticals Gains 1.08%: Mixed Technical Signals Amid Strong Fundamentals

29 June: Surge in Derivatives Open Interest Signals Bullish Positioning

Glenmark Pharmaceuticals began the week on a strong note with a significant 15.21% increase in open interest in its derivatives segment, rising to 59,301 contracts from 51,470 the previous session. This surge was accompanied by a robust trading volume of 71,287 contracts, reflecting heightened market activity and investor interest. The futures segment alone accounted for a notional value of approximately ₹1,47,494 lakhs, while options contributed ₹44,774.33 crores, underscoring substantial institutional and retail participation.

The stock price closed at Rs.2,186.20, having touched an intraday high of Rs.2,216.30, representing a 2.87% gain on the day. This outperformance contrasted with the Sensex’s decline of 0.40%, highlighting Glenmark’s relative strength within the broader market. The price action, combined with rising open interest, suggested fresh bullish bets rather than short covering, indicating market participants were positioning for further upside.

Technically, the stock traded above its 5-day, 20-day, 100-day, and 200-day moving averages, signalling sustained medium- and long-term strength, although it remained slightly below the 50-day moving average, hinting at near-term resistance. Despite a dip in delivery volumes, the liquidity profile remained adequate for sizeable trades, supporting active market participation.

2 July: Mojo Grade Downgrade to Hold Amid Technical Setbacks

On 2 July, MarketsMOJO downgraded Glenmark Pharmaceuticals’ Mojo Grade from Buy to Hold, reflecting a shift in technical indicators despite the company’s strong fundamentals. The downgrade was driven by a transition from mildly bullish to sideways momentum, signalling uncertainty in the stock’s near-term direction.

Fundamentally, Glenmark remains robust with a profit after tax of ₹1,133.97 crores over the last six months, representing a growth rate of 103.40%. Return on Capital Employed (ROCE) stands at 40.16%, and Return on Equity (ROE) at 26.9%, placing the company among the top 1% of rated stocks by MarketsMOJO. The stock trades at a favourable Price to Book ratio of 5.8 and a low PEG ratio of 0.2, indicating undervaluation relative to earnings growth potential.

Despite these strengths, the stock’s short-term returns were negative over the one-week (-1.02%) and one-month (-1.98%) periods, underperforming the Sensex’s modest gains. The stock closed at Rs.2,157.70 on 1 July, down 2.14% from the previous day, and remained below its 52-week high of Rs.2,471.05. These factors contributed to a more cautious stance, with the Mojo Score adjusted to 61.0.

2 July: Technical Momentum Shifts to Sideways Amid Mixed Signals

The technical landscape for Glenmark Pharmaceuticals further evolved on 2 July, with key indicators signalling a shift from mildly bullish to sideways momentum. The Moving Average Convergence Divergence (MACD) on weekly and monthly charts turned mildly bearish, indicating waning upward momentum. The Relative Strength Index (RSI) remained neutral, suggesting neither overbought nor oversold conditions.

Bollinger Bands showed bearish tendencies on the weekly chart but retained mild bullishness monthly, reflecting short-term price pressure amid longer-term support. Daily moving averages continued to show mild bullishness, while the Know Sure Thing (KST) oscillator and On-Balance Volume (OBV) presented mixed bearish and neutral signals. Dow Theory analysis indicated no definitive trend, reinforcing the sideways technical stance.

These mixed signals suggest a consolidation phase, with the stock trading between support near Rs.2,150 and resistance around Rs.2,220 to Rs.2,250. Investors are advised to monitor momentum and volume indicators closely for confirmation of any directional breakout or breakdown.

3 July: Week Closes with Modest Gain Amid Mixed Market Signals

Glenmark Pharmaceuticals closed the week at Rs.2,209.85 on 3 July, up 0.68% from the previous day’s close of Rs.2,195.00. The stock’s weekly gain of 1.08% was slightly below the Sensex’s 1.31% rise, reflecting a cautious market environment. Trading volumes remained healthy, with 16,784 shares changing hands, supporting liquidity.

The stock’s price action over the week was characterised by volatility and mixed technical signals, with the initial bullish momentum on 29 June giving way to consolidation and sideways movement. Despite this, Glenmark’s long-term performance remains strong, with a 5-year return of 230.43% and a three-year return of 219.23%, significantly outperforming the Sensex over these periods.

Key Takeaways

Positive Signals: The week opened with a strong surge in derivatives open interest and volume, indicating bullish market positioning and fresh money entering the stock. Glenmark’s solid fundamentals, including robust earnings growth, high ROCE and ROE, and attractive valuation metrics, continue to underpin its long-term investment appeal. The stock’s long-term returns significantly outpace the Sensex, reflecting sustained operational strength.

Cautionary Signals: Despite fundamental strength, the downgrade to a Hold rating and the shift in technical momentum to sideways reflect emerging near-term uncertainties. Mixed technical indicators such as bearish MACD and KST oscillators, neutral RSI, and sideways Dow Theory trends suggest consolidation and lack of clear directional momentum. The stock’s short-term underperformance relative to the Sensex and declining delivery volumes also warrant careful monitoring.

Investors should balance Glenmark’s strong financial and operational profile against the current technical caution, watching for confirmation of momentum shifts before increasing exposure.

Conclusion

Glenmark Pharmaceuticals Ltd. experienced a week of mixed momentum, with a modest 1.08% gain that slightly lagged the Sensex’s 1.31% advance. The week was characterised by a notable surge in derivatives open interest signalling bullish sentiment, followed by a downgrade in the Mojo Grade to Hold due to technical setbacks and a shift to sideways momentum. While the company’s fundamentals remain robust, the technical indicators suggest a consolidation phase amid market uncertainty.

Going forward, Glenmark’s stock will likely require a clear breakout from its current trading range to resume its upward trajectory. Investors should remain attentive to technical signals and volume trends while recognising the company’s strong long-term growth and valuation appeal within the pharmaceuticals sector.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →